Switch theme
Sign up to access all valuation multiples
Assure Tech (Hangzhou) Co Ltd is a biotechnology company. The company is engaged in research & development, production, sell of diagnostic reagents, POCT and biological materials.
2008
n/a
LTM Revenue n/a
LTM EBITDA n/a
$371M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Assure Tech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Assure Tech achieved revenue of $69.4M and an EBITDA of $28.8M.
Assure Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Assure Tech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $850M | $69.4M | XXX | XXX | XXX |
| Gross Profit | $143M | $635M | XXX | XXX | XXX |
| Gross Margin | 17% | 916% | XXX | XXX | XXX |
| EBITDA | $492M | $28.8M | XXX | XXX | XXX |
| EBITDA Margin | 58% | 42% | XXX | XXX | XXX |
| Net Profit | $102M | $419M | XXX | XXX | XXX |
| Net Margin | 12% | 605% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Assure Tech's stock price is CNY 37 (or $5).
Assure Tech has current market cap of CNY 4.7B (or $649M), and EV of CNY 2.7B (or $371M).
See Assure Tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $371M | $649M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Assure Tech has market cap of $649M and EV of $371M.
Assure Tech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Assure Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Assure Tech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $371M | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.9x | XXX | XXX | XXX |
| P/E | 33.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAssure Tech's NTM/LTM revenue growth is n/a
Assure Tech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Assure Tech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Assure Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Assure Tech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -92% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -94% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 37% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Assure Tech acquired XXX companies to date.
Last acquisition by Assure Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Assure Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Assure Tech founded? | Assure Tech was founded in 2008. |
| Where is Assure Tech headquartered? | Assure Tech is headquartered in China. |
| Is Assure Tech publicy listed? | Yes, Assure Tech is a public company listed on SHG. |
| What is the stock symbol of Assure Tech? | Assure Tech trades under 688075 ticker. |
| When did Assure Tech go public? | Assure Tech went public in 2021. |
| Who are competitors of Assure Tech? | Similar companies to Assure Tech include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Assure Tech? | Assure Tech's current market cap is $649M |
| What is the current revenue growth of Assure Tech? | Assure Tech revenue growth between 2023 and 2024 was -92%. |
| Is Assure Tech profitable? | Yes, Assure Tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
